New York Times This morning, a long interview between columnist Ross Dutt and Venture Capitalist and PayPal founder Peter Thale. There is a reason for being published in the opinion section.
The bag, a Trump Booster, whose ally – Vice President JD Venus – has now been filled with dirt, was given a free rule to discuss multiple topics about more than an hour of softball. Is Greita Thanburg literally the Antichrist? Are the three major ideological schools of the European Environment, “Islamic Shariah Law” and “Chinese Communist Absolute Take Over”? Is Ai “awake” and Elon is capable of going to Mars? Peter looks like! Perhaps “just asking questions” can include school of journalism “Hey, what are you talking about?“To his reservoir.
It is acknowledged that many of these claims fall into the realm of things that exist with at least one remarkable exception rather than the facts in Telia’s brain palace. Relatively sirply in his chat, Peter told Ross the following (our emphasis):
If we look at the biotech, something like dementia, Alzheimer’s We have developed zero progress in 40 to 50 years. People are completely trapped on beta amilides. It is obviously not working. This is just a kind of stupid racket where people are just strengthening themselves.
This is a beautiful bold claim! This is also completely wrong.
“There was no cure for Alzheimer’s illness,” Sterling Johnson, a professor at the University of Wisconsin, Medicine, Wisconsin, told Anggzat. “What we have been able to do in the last 20 years has been very unusual. We have developed markers that start the disease when the disease begins, using amaloid markers and Tao bio -markers, we know that this disease begins 20 years before the symptoms, and an important thing to know is whether we are going to avoid this disease. “
At this time, Alzheimer’s is unhealthy. But the absence of a miracle treatment does not negate the achievements that are still in detection and prevention. “The first treatment was a window dressing treatment. It is like treating symptoms as you will treat the cold (…) the first generation of amaloid therapy was such a point of view where it resolved the symptoms by promoting neurons available to brain cells and increasing neuro transmitters.” Johnson, whose team runs the largest and longest study about people at risk of developing Alzheimer’s disease, added, “Now we have opportunities to modify the biology of the disease via amaloid paths, but we are also focused on other proteinopathy – which is here.”
The bag, a famous lawyer for the expansion of radical life (including interest in the blood of young people, is interested in injection of himself) describes the state of scientific research in the area. But at this time the groundwork is being done. Professor Johnson pointed to a monoclonal antibody called Gantineromab. In the initial examination of 73 participants with inherited variations, which causes them to produce amaloids in the brain, it reduced the number of participants who practically developed Alzheimer’s symptoms. “Three prevention trials are still taking place in the biggest phase.” They are using leukanimab and Donimab, two other monoclonal remedies, about which Johnson has made it clear that “beta is already better than gantinarromab to clean.”
For someone who fashioned himself as a heteroidox thinker, the bag seems to have certainly stumbled with the current Trump administration’s head of FDA Robert F. Kennedy Jr. He claimed that the NIH was “eliminating another assumption” because of “corruption”.
Not surprisingly, the Alzheimer’s Association has termed it “clearly wrong”.
“In fact, in the recent 10 years available (2014-2023), less than 14 % of the new National Institutes of Health (NIH) Alzheimer’s plans have been focused on the amaloid beta beta. Ameleide is clearly wrong to exclude other goals.”
If I, personally, wanted a more strong medical research and an opportunity in eternal life (I don’t), giving grease the wheels of the large -scale funding administration for science would be a strange way to perform it. But this is the inequality we expect from the Tech Eleigches: they say what they benefit from, even if it is nonsense on his face, even if a moment’s reflection will clearly prove it. The shameful thing is that the record paper gives them free rule.
Update June 27, 2025 2: 15et: The story now includes additional clinical trial information.
